Posted by ABMN Staff on May 19th, 2024
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) had its target price reduced by equities research analysts at Mizuho from $9.00 to $3.00 in a report released on Friday, Benzinga reports. The firm currently has a “buy”...
More of this article »